Novo Nordisk A/ S stock rebounds on UBT251 trial data amid CEO turmoil and buyback momentum

Novo Nordisk A/S (ISIN: DK0062498333) reports strong phase 2 results for triple agonist UBT251, signaling potential revival in GLP-1 competition as shares stabilize post-CEO change. DACH investors eye valuation at 11x earnings on Copenhagen exchange in DKK.

Novo Nordisk A/S has unveiled promising phase 2 trial data for its triple agonist drug UBT251, achieving 19.7% average weight loss after 24 weeks in collaboration with The United Laboratories International Holdings Limited. This development arrives as the company navigates a recent CEO change that triggered a nearly 50% stock plunge and lowered annual guidance, heightening uncertainty in the GLP-1 market dominated by rivals like Eli Lilly. For DACH investors, the update offers a potential entry point into a battered pharma leader trading at a compelling 11 times earnings, far below S&P 500 averages, with ongoing DKK 15 billion share buybacks underscoring management confidence.

As of: 17.03.2026

By Dr. Elena Voss, Senior Pharma Equity Analyst – Tracking GLP-1 pipeline catalysts and European biotech valuations amid shifting obesity drug leadership.

UBT251 Trial Breakthrough Cuts Through Competitive Noise

The phase 2 results for UBT251 mark a critical milestone for Novo Nordisk A/S. Patients in the trial lost an average of 19.7% body weight over 24 weeks, positioning the drug as a contender in the triple agonist category. This efficacy rivals early data from Eli Lilly's retatrutide, which showed 28.7% loss over 68 weeks, but UBT251's shorter-term potency suggests sustained potential if phase 3 confirms durability.

Developed through a partnership with The United Laboratories, UBT251 targets unmet needs in obesity and diabetes care. Novo Nordisk's core franchises – Ozempic and Wegovy – face pricing pressures and supply constraints, making pipeline advances essential for regaining momentum. The market reacted positively, viewing this as a hedge against eroding GLP-1 dominance.

Investors should note the trial's collaboration structure. While Novo benefits from shared development costs, milestone payments and royalties could dilute upside. Still, success here bolsters Novo's biopharma segment, which includes hemophilia and growth hormone therapies beyond diabetes.

CEO Transition Fuels Year-Long Selloff

A recent CEO change at Novo Nordisk A/S precipitated a sharp nearly 50% drop in its stock price over the past year on the Copenhagen exchange in DKK. The leadership shift came alongside reduced annual guidance, amplifying concerns over execution in a hyper-competitive GLP-1 landscape. New CEO Mike Doustdar now steers the ship, emphasizing patient access through partnerships like the recent Hims & Hers deal for Ozempic and Wegovy distribution.

This partnership drops a patent lawsuit against the telehealth platform, prioritizing FDA-approved drugs over compounded alternatives. It counters discounting by rivals, safeguarding Novo's pricing power. However, refiling rights preserve legal options if needed.

The leadership upheaval underscores broader challenges: supply chain bottlenecks for Wegovy and regulatory scrutiny on GLP-1 side effects. DACH portfolios holding Novo shares saw amplified volatility, but the buyback program signals board commitment to shareholder value.

Massive Share Buyback Demonstrates Confidence

Novo Nordisk A/S launched a DKK 15 billion B-share repurchase program starting February 4, 2026, with DKK 3.8 billion allocated through May 4. By March 13, the company had already bought back 6.58 million shares, reducing share count and boosting EPS potential. This move on the Copenhagen exchange in DKK counters dilution fears and supports valuation in a downturn.

Buybacks align with strong fundamentals: Q4 revenue hit $12.43 billion, beating estimates, with EPS of $1.01 versus $0.90 expected. Net margins at 33% and ROE of 68.91% highlight profitability despite headwinds. A $1.2751 dividend, payable April 8 (ex-date March 30), adds income appeal for yield-seeking DACH investors.

Debt-to-equity at 0.61 remains manageable, though current ratio of 0.80 flags liquidity watchpoints. The program, detailed in SEC filings, prioritizes B shares matching ISIN DK0062498333, traded primarily on Nasdaq Copenhagen.

GLP-1 Rivalry Heats Up with Eli Lilly

Eli Lilly's retatrutide sets a high bar with 28.7% weight loss over 68 weeks, pressuring Novo's UBT251 to prove long-term efficacy. Novo Nordisk's Ozempic and Wegovy pioneered GLP-1s, but competition erodes market share as copycats flood telehealth channels. UBT251's 19.7% in 24 weeks offers hope, but phase 3 data will be decisive.

Pipeline depth matters in pharma. Novo's diabetes/obesity segment – insulins, GLP-1s, delivery systems – drives 80% of revenue, with biopharma adding diversification. Patent cliffs loom for older products like NovoLog, necessitating launches like Saxenda expansions.

Regulatory risks persist: FDA probes into compounded semaglutides threaten unapproved rivals, benefiting Novo's approved portfolio. DACH regulators mirror this scrutiny, favoring branded therapies in reimbursement schemes.

Investor Relevance: Valuation Discount Beckons

Novo Nordisk A/S trades at 11x earnings, a stark discount to S&P 500's 24x, on Nasdaq Copenhagen in DKK. Analysts issue 'Hold' consensus with targets like Goldman Sachs' $41 on NYSE:NVO equivalent, post-downgrades. Institutional ownership at 11.54% reflects caution, but buybacks and dividends attract value hunters.

For DACH investors, Novo fits defensive pharma allocations. Exposure to 170 markets, including strong EU presence, aligns with regional healthcare spending. 50-day moving average around $50 on NYSE signals stabilization, with 200-day at $51.73.

Portfolio implications: Pair with diversified holdings to mitigate GLP-1 concentration. Long-term, pipeline wins could drive re-rating, especially if UBT251 advances reimbursement in Germany, Austria, Switzerland.

Risks and Open Questions Loom Large

Legal probes by firms like Portnoy Law follow a 16.43% ADR drop to $39.63 on NYSE February 23, tied to undisclosed issues. Competition intensifies as hyperscalers and generics eye GLP-1s. Supply ramps for Wegovy remain bottlenecked, capping revenue.

Macro pressures: Inflation hits R&D costs; currency swings affect DKK-denominated results for euro-based DACH funds. Patent exposures on key insulins demand vigilant pipeline execution. If UBT251 falters in phase 3, valuation could compress further.

Geopolitical risks in China partnerships add layers, though diversification via 68,800 employees across 80 countries buffers. Investors must weigh rebound potential against execution hurdles.

DACH Investor Perspective: Strategic Fit in Turbulence

German-speaking investors favor Novo's stability in chronic disease markets mirroring rising EU obesity rates. Reimbursement pathways in DACH health systems prioritize GLP-1 efficacy data, favoring UBT251 if approved. Copenhagen listing offers direct access, with ADRs on NYSE for US exposure.

Compared to peers, Novo's ROE dominance persists despite volatility. DACH funds increased stakes post-earnings beat, eyeing buyback accretion. Cautious framing: Monitor Q1 guidance for guidance reiteration amid CEO bedding-in.

Overall, the stock's arc – from GLP-1 pioneer to challenged incumbent – tests conviction. Current setup rewards patient capital blending dividend yield, buybacks, and pipeline optionality.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.